I agree that this site is using cookies. You can find further informations here.
X
Sehn, L. H.
326  results:
Search for persons X
?
1

Impact of the Dark Zone Signature on Central Nervous System..:

Alduaij, W. ; Jiang, A. ; Collinge, B....
Hematological Oncology.  41 (2023)  S2 - p. 294-296 , 2023
Link: https://doi.org/10.1002/..
 
?
2

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WI..:

Sehn, L. H. ; Bartlett, N. L. ; Matasar, M....
Hematological Oncology.  41 (2023)  S2 - p. 122-125 , 2023
Link: https://doi.org/10.1002/..
 
?
3

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES ..:

Herrera, A. F. ; Tracy, S. ; Sehn, L. H....
Hematological Oncology.  41 (2023)  S2 - p. 175-177 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Analysis of Real‐World Treatment Patterns and Outcomes Amon..:

Sehn, L. H. ; Wang, A. ; Yu, J....
Hematological Oncology.  41 (2023)  S2 - p. 373-375 , 2023
Link: https://doi.org/10.1002/..
 
?
5

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R..:

Sehn, L. H ; Chamuleau, M. ; Lenz, G....
Hematological Oncology.  41 (2023)  S2 - p. 849-850 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Tafasitamab plus lenalidomide versus standard of care as se..:

Sehn, L. H. ; Kuruvilla, J. ; Salles, G....
Hematological Oncology.  41 (2023)  S2 - p. 441-442 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Subgroup analysis of elderly patients (pts) with diffuse la..:

Hu, B. ; Reagan, P. M. ; Sehn, L. H....
Hematological Oncology.  41 (2023)  S2 - p. 416-418 , 2023
Link: https://doi.org/10.1002/..
 
?
8

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDO..:

Sehn, L. H. ; Hübel, K. ; Luminari, S....
HemaSphere.  6 (2022)  - p. 993-994 , 2022
Link: https://doi.org/10.1097/..
 
?
9

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUB..:

Sehn, L. H. ; Avivi, I. ; Brody, J....
HemaSphere.  6 (2022)  - p. 2004-2005 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN P..:

Matasar, M. ; Bartlett, N. L. ; Sehn, L. H....
HemaSphere.  6 (2022)  - p. 1016-1017 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMEN..:

Morschhauser, F. ; Jiang, Y. ; Jardin, F....
HemaSphere.  6 (2022)  - p. 1076-1077 , 2022
Link: https://doi.org/10.1097/..
 
?
12

THE MUTATIONAL LANDSCAPE OF DOUBLE/TRIPLE‐HIT HIGH‐GRADE B‐..:

Collinge, B. J. ; Hilton, L. K. ; Wong, J....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
13

The Impact of Surveillance Imaging After Curative Intent Ra..:

Urban, R. ; Chow, R. ; Pickles, T....
International Journal of Radiation Oncology*Biology*Physics.  111 (2021)  3 - p. S105-S106 , 2021
Link: https://doi.org/10.1016/..
 
?
14

RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYT..:

Villa, D. ; Hoster, E. ; Hermine, O....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
15

WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLB..:

Hilton, L. K ; Collinge, B ; Rushton, C. K...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
1-15